OTC · ADXS
Ayala Pharmaceuticals, Inc.
$0.60$0.00 (0.0%)
Ayala Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.65% below the high.
Loading market information…
OTC · RNUGF · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ReNeuron Group plc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ReNeuron Group plc’s next earnings report is currently expected on Nov 11, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ReNeuron Group plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to improve outcomes for individuals suffering from stroke-related disabilities. Additionally, the company is progressing with its human retinal progenitor cell therapy, which is currently in Phase 2 clinical trials, aiming to address retinitis pigmentosa, a condition leading to blindness. Beyond these primary therapies, ReNeuron is also developing CTX-derived exosomes, which are microscopic packages of biological information released by CTX cells, and these are presently in the preclinical research stage. The company also offers licenses for its proprietary ReNcell product line. Demonstrating a commitment to collaborative research, ReNeuron has partnered with University College London to explore methods for generating immune cells from induced pluripotent stem cells, with the ultimate goal of developing novel anti-cancer cell therapies. Established in 1997, ReNeuron Group plc is headquartered in Pencoed, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.28+15.72% vs estimate |
| $43.20K-98.01% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.60$0.00 (0.0%)
Ayala Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.65% below the high.
$0.00$0.00 (0.0%)
America Great Health’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
CA$0.07-CA$0.01 (-7.14%)
Restart Life Sciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 51.85% below the high.
$0.00$0.00 (0.0%)
Health Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
CA$0.32-CA$0.04 (-9.86%)
Grey Matters Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.44% below the high.
$0.00$0.00 (0.0%)
AXIM Biotechnologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.66% below the high.
CA$0.01+CA$0.01 (+100.0%)
Appili Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.22$0.00 (0.0%)
SB Technology Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.21% below the high.
